Absci (NASDAQ:ABSI – Get Rating) is one of 39 publicly-traded companies in the “Commercial physical research” industry, but how does it compare to its competitors? We will compare Absci to similar companies based on the strength of its profitability, earnings, risk, valuation, institutional ownership, analyst recommendations and dividends.
This table compares Absci and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This table compares Absci and its competitors gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Absci||$4.78 million||-$100.96 million||-1.16|
|Absci Competitors||$2.80 billion||$101.15 million||13.55|
Absci’s competitors have higher revenue and earnings than Absci. Absci is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.
This is a summary of current ratings and recommmendations for Absci and its competitors, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Absci currently has a consensus target price of $24.00, suggesting a potential upside of 521.76%. As a group, “Commercial physical research” companies have a potential upside of 40.00%. Given Absci’s higher probable upside, equities research analysts plainly believe Absci is more favorable than its competitors.
Insider and Institutional Ownership
40.0% of Absci shares are held by institutional investors. Comparatively, 59.5% of shares of all “Commercial physical research” companies are held by institutional investors. 11.4% of shares of all “Commercial physical research” companies are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Absci competitors beat Absci on 11 of the 12 factors compared.
Absci Company Profile (Get Rating)
Absci Corporation, a drug and target discovery company, provides biologic drug candidates and production cell lines using integrated drug creation platform for partners in the United States. Its integrated drug creation platform enables the creation of biologics by unifying the drug discovery and cell line development processes into one process. Absci Corporation was founded in 2011 and is headquartered in Vancouver, Washington.
Receive News & Ratings for Absci Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Absci and related companies with MarketBeat.com's FREE daily email newsletter.